Drug Interaction Study on Linaprazan Glurate Capsules
Key facts
- Who runs it
- Jiangsu Sinorda Biomedicine Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 56 people enrolled
- Started
- 8 Sept 2025
- Ended
- 15 Dec 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- Linaprazan Glurate Capsules
- Bismuth Potassium Citrate Capsules
- Amoxicillin Capsules
- Clarithromycin tablets
- Esomeprazole Magnesium Enteric-coated Tablets
- Record updated
- 6 January 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Age range: 18 to 55 years old (including 18 and 55)
- Male weight ≥50.0 kg, female weight ≥45.0 kg; Body Mass Index (BMI) between 19.0 and 26.0 kg/m²(including critical value); BMI=weight/height2 (m2)
- Part 1 Study and Part 2 Study:; Part 1: Subjects must be Helicobacter pylori-negative at screening; Part 2: Subjects must be Helicobacter pylori-positive at screening
- From signing informed consent until 3 months after study completion, subjects must: Implement appropriate and effective contraception to prevent pregnancy (applies to subject or partner); Refrain from sperm donation or egg donation plans
- Subjects must fully comprehend the trial content, voluntarily participate in the trial, Provide written informed consent
Who cannot take part
- Subjects with use of any investigational product within 3 months prior to screening
- Subjects with use within 30 days prior to screening of Prescription drugs, Over-the-counter ,OTC) medications, Herbal medicines, Dietary supplements
- Subjects with major surgery within 3 months prior to screening,and planned surgery during trial participation
- Subjects who have used illicit drugs within the 3 months prior to screening, or have a history of drug abuse within the past 12 months, or whose urine drug abuse screening test result is positive
- Subjects who regularly consumed alcohol within the 3 months prior to screening (i.e., consuming more than 14 standard units per week; 1 unit = 360mL of beer, or 45mL of 40% spirits, or 150mL of wine), or who are unwilling to abstain from alcohol or any alcohol-containing products for 48 hours prior to dosing and during the trial, or whose alcohol breath test result is positive
- Subjects who smoked an average of >5 cigarettes per day within the 30 days prior to screening; or who cannot guarantee abstinence from smoking from the signing of the informed consent form until the end of the study
- Subjects who have been vaccinated within the 3 months prior to screening or plan to be vaccinated during the trial period
- Subjects who consumed excessive amounts of tea, coffee, or caffeinated beverages (more than 8 cups per day; 1 cup = 250mL) within the 4 weeks prior to screening
- Subjects who consumed special diets (including pitaya, mango, grapefruit, pomelo, lime, starfruit, or foods/beverages prepared from them, or any caffeinated foods/beverages, alcoholic beverages, or other foods/beverages known to affect drug absorption, distribution, metabolism, or excretion) within 48 hours prior to the first dose
- Subjects with history of diseases in the following systems (also investigator-determined as ineligible): Central nervous system, Cardiovascular system, Respiratory system, Digestive system, Endocrine system, Immune system, Neurological/Psychiatric systems, Hematologic/Lymphatic systems, Musculoskeletal system
- Gastrointestinal/Surgical History: History of gastrointestinal diseases or surgeries including:Gastric surgery (except pyloromyotomy for infantile pyloric stenosis), Cholecystectomy, Vagotomy, Bowel resection, Any surgery potentially affecting GI motility, pH, or absorption, Conditions impacting drug ADME: Dysphagia, Vomiting, Severe diarrhea
- Infectious Disease Screening: Positive results for any at screening: Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), Treponema pallidum antibody (TP-Ab)
- Subjects who are intolerant to venipuncture, have difficulty with blood collection, or have a history of needle or blood phobia/syncope
- Subjects known as Hypersensitivity History: Known allergy to: Linaprazan Glurate capsules, Esomeprazole (Part 2 only), Penicillin, Macrolide antibiotics, Any component of bismuth potassium citrate;History of severe immediate hypersensitivity to: Other macrolide antibiotics, β-lactam agents (e.g., cephalosporins, carbapenems, monobactams),Multiple drug hypersensitivity (e.g., allergic reactions to ≥2 medications/foods)
- Clinically Significant Abnormalities at Screening: Abnormalities deemed clinically significant by investigators based on: Medical history review, Vital signs, Physical examination, 12-lead ECG, Laboratory tests: Complete blood count (CBC), Blood chemistry, Urinalysis, Coagulation tests
- Subjects with Penicillin sodium skin test positivity during screening
- Subjects with use of potassium-competitive acid blockers (P-CABs) within 3 months prior to screening
- Cardiac Abnormalities: Clinically significant ECG abnormality history, Family history of Long QT Syndrome (grandparents, parents, siblings), Screening QTcF prolongation: 450 msec in males, 470 msec in females
- Subjects with blood donation (whole blood/component) ≥400 mL within 3 months (excluding menstrual loss),Blood transfusion or blood product use within 3 months
- Pregnant or lactating women
- Subjects with special dietary requirements who cannot comply with the standardized diet, or who have difficulty swallowing
- Subjects deemed unsuitable for participation by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a drug-drug interaction (DDI) investigation involving Linaprazan Glurate capsules and a combination of clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules. The study plan is divided into two parts: one involving Hp-negative healthy subjects and the other involving Hp-positive subjects.
The 3 groups in the trial
- Linaprazan Glurate Capsules 50mg BID, consecutive 7-day dosing per periodTreatment being tested
Glurate Capsules Capsules 50mg, BID, consecutive 7-day dosing per period in Part 1.
Treatment: Linaprazan Glurate Capsules, Amoxicillin Capsules, and Clarithromycin tablets
- Linaprazan Glurate Capsules 50mg BID, consecutive 14-day dosingTreatment being tested
Linaprazan Glurate Capsules 50mg BID, consecutive 14-day dosing in part 2.
Treatment: Linaprazan Glurate Capsules, Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin tablets
- Esomeprazole Magnesium Enteric-coated Tablets 20mg BID, consecutive 14-day dosing.Treatment being tested
Esomeprazole Magnesium Enteric-coated Tablets 20mg, BID in Part 2.
Treatment: Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, Clarithromycin tablets, and Esomeprazole Magnesium Enteric-coated Tablets
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Drug Interaction Study on Linaprazan Glurate Capsules, Clarithromycin Tablets, Amoxicillin Capsules, and Bismuth Potassium Citrate Capsules
- Record updated
- 6 January 2026